Amantadine
Administration
- Type: Antiviral, anticholinergics
- Dosage Forms: capsule or tablet, syrup
- Routes of Administration: Oral
- Common Trade Names: Gocovri
Adult Dosing
Influenza A
- 100 mg BID or 200 mg daily PO
Parkinsonism, extrapyramidal disease
- 100-200 mg BID
Neuroleptic malignant syndrome
- 100mg PO initially
- Titrate up as needed to max dose 200mg q12hr
Pediatric Dosing
Influenza, 1-9 years old
- 2.2-4.4 mg/kg PO BID
Influenza, >9 years old
- 100 mg PO BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- CrCl 30-50 mL/min: 200 mg PO on first day, then 100 mg/day
- CrCl 15-29 mL/min: 200 mg PO on first day, then 100 mg every other day
- CrCl <15 mL/min or on HD: 200mg weekly
- Hepatic dosing: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- CHF, hypotension, dysrhythmia, tachycardia, cardiac arrest
- Pulmonary edema, acute respiratory failure
- Malignant melanoma
- Leukopenia, agranulocytosis, neutropenia
- Neuroleptic malignant syndrome
- Suicidal ideation
Common
- Nausea, diarrhea, constipation, lack of appetite
- Headache
- Fatigue, dizziness, confusion, ataxia
- Anxiety, insomnia, depression, irritability, hallucinations, dream disorder
- Orthostatic hypotension
- Peripheral edema
Pharmacology
- Half-life: 10-25h
- Metabolism: Not appreciably metabolized; small amounts of acetyl metabolite identified
- Excretion: Renal
Mechanism of Action
- Interferes with the function of viral M2 protein, preventing release of viral nucleic acids into host cell